MADRIGAL PHARMACEUTICALS, INC. Accounts Receivable
MADRIGAL PHARMACEUTICALS, INC. (MDGL) had Accounts Receivable of $192.31 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2026-07-30
- 2026-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $192.31M.
- 2026-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $187.36M.
- 2025-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $134.48M.
- 2025-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $113.28M.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2026-06-30 | $192.31M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $187.36M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $134.48M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $113.28M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $79.23M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $61.43M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $53.82M 10-K · filed 2026-02-19 |
| 2024-09-30 | $30.46M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $6.90M 10-Q · filed 2024-08-07 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |